Dixie Esseltine

8.8k total citations
44 papers, 3.1k citations indexed

About

Dixie Esseltine is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Dixie Esseltine has authored 44 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Hematology, 25 papers in Oncology and 23 papers in Molecular Biology. Recurrent topics in Dixie Esseltine's work include Multiple Myeloma Research and Treatments (29 papers), Protein Degradation and Inhibitors (12 papers) and Peptidase Inhibition and Analysis (10 papers). Dixie Esseltine is often cited by papers focused on Multiple Myeloma Research and Treatments (29 papers), Protein Degradation and Inhibitors (12 papers) and Peptidase Inhibition and Analysis (10 papers). Dixie Esseltine collaborates with scholars based in United States, Italy and United Kingdom. Dixie Esseltine's co-authors include Paul G. Richardson, Kenneth C. Anderson, Bart Barlogie, Sundar Jagannath, James R. Berenson, Seema Singhal, David P. Schenkein, Julian Adams, Gordan Srkalović and David Irwin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PEDIATRICS.

In The Last Decade

Dixie Esseltine

44 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dixie Esseltine United States	22	1.9k	1.8k	1.6k	539	506	44	3.1k
Jatin J. Shah United States	31	2.0k 1.1×	2.4k 1.3×	1.6k 1.0×	417 0.8×	553 1.1×	208	3.8k
Donna M. Weber United States	28	2.7k 1.4×	2.4k 1.3×	1.6k 1.0×	616 1.1×	413 0.8×	132	3.6k
Martin Kropff Germany	26	2.5k 1.4×	2.1k 1.2×	1.7k 1.0×	368 0.7×	183 0.4×	69	3.1k
Vincenzo Callea Italy	26	1.3k 0.7×	1.1k 0.6×	797 0.5×	771 1.4×	630 1.2×	85	2.2k
RJ Jones United States	24	1.7k 0.9×	725 0.4×	941 0.6×	688 1.3×	319 0.6×	33	2.8k
Giulia Perrone Italy	20	1.5k 0.8×	1.3k 0.7×	1.2k 0.7×	248 0.5×	207 0.4×	53	2.4k
Peter Gimsing Denmark	31	2.1k 1.1×	1.9k 1.0×	1.4k 0.9×	301 0.6×	176 0.3×	111	3.1k
Yaping Shou United States	25	1.8k 1.0×	1.1k 0.6×	686 0.4×	1.5k 2.7×	439 0.9×	68	3.1k
Sebastian Grosicki Poland	21	1.9k 1.0×	1.3k 0.8×	1.2k 0.7×	1.2k 2.3×	878 1.7×	158	3.1k
John C. Byrd United States	19	1.7k 0.9×	1.5k 0.8×	720 0.4×	1.4k 2.5×	1.0k 2.0×	81	3.7k

Countries citing papers authored by Dixie Esseltine

Since Specialization

Citations

This map shows the geographic impact of Dixie Esseltine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dixie Esseltine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dixie Esseltine more than expected).

Fields of papers citing papers by Dixie Esseltine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dixie Esseltine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dixie Esseltine. The network helps show where Dixie Esseltine may publish in the future.

Co-authorship network of co-authors of Dixie Esseltine

This figure shows the co-authorship network connecting the top 25 collaborators of Dixie Esseltine. A scholar is included among the top collaborators of Dixie Esseltine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dixie Esseltine. Dixie Esseltine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mateos, María‐Victoria, Sara Bringhen, PG Richardson, et al.. (2014). Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica. 99(6). 1114–1122. 35 indexed citations

Zangari, Maurizio, Shmuel Yaccoby, Lisa M. Pappas, et al.. (2010). A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients. Haematologica. 96(2). 333–336. 45 indexed citations

Mateos, María‐Victoria, Paul G. Richardson, Rudolf Schlag, et al.. (2010). Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial. Journal of Clinical Oncology. 28(13). 2259–2266. 312 indexed citations

Dees, Elizabeth Claire, Bert H. O’Neil, Celeste Lindley, et al.. (2008). A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology. 63(1). 99–107. 21 indexed citations

Zangari, Maurizio, Dixie Esseltine, Federica Cavallo, et al.. (2007). Predictive value of alkaline phosphatase for response and time to progression in bortezomib‐treated multiple myeloma patients. American Journal of Hematology. 82(9). 831–833. 23 indexed citations

Viala, Muriel, Asha Bhakar, Christine de la Loge, et al.. (2007). Patient-reported outcomes helped predict survival in multiple myeloma using partial least squares analysis. Journal of Clinical Epidemiology. 60(7). 670–679.e3. 27 indexed citations

González-Angulo, Ana M., James M. Reuben, Daniel J. Booser, et al.. (2006). Bortezomib (VELCADE®) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Annals of Oncology. 17(5). 813–817. 113 indexed citations

Zangari, Maurizio, Shmuel Yaccoby, Federica Cavallo, Dixie Esseltine, & Guido Tricot. (2006). Response to Bortezomib and Activation of Osteoblasts in Multiple Myeloma. Clinical Lymphoma & Myeloma. 7(2). 109–114. 37 indexed citations

Stubblefield, Michael D., Susan F. Slovin, Barbara MacGregor‐Cortelli, et al.. (2006). An Electrodiagnostic Evaluation of the Effect of Pre-existing Peripheral Nervous System Disorders in Patients Treated with the Novel Proteasome Inhibitor Bortezomib. Clinical Oncology. 18(5). 410–418. 17 indexed citations

10.

Gerecitano, John F., André Goy, James R. Wright, et al.. (2006). Drug‐induced cutaneous vasculitis in patients with non‐Hodgkin lymphoma treated with the novel proteasome inhibitor bortezomib: a possible surrogate marker of response?. British Journal of Haematology. 134(4). 391–398. 36 indexed citations

11.

Jagannath, Sundar, Paul G. Richardson, Bart Barlogie, et al.. (2006). Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.. PubMed. 91(7). 929–34. 123 indexed citations

12.

Richardson, Paul G., Hannah Briemberg, Sundar Jagannath, et al.. (2006). Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib. Journal of Clinical Oncology. 24(19). 3113–3120. 480 indexed citations

13.

Zangari, Maurizio, Dixie Esseltine, Choon‐Kee Lee, et al.. (2005). Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. British Journal of Haematology. 131(1). 71–73. 146 indexed citations

14.

Jagannath, Sundar, Bart Barlogie, James R. Berenson, et al.. (2005). Bortezomib in recurrent and/or refractory multiple myeloma. Cancer. 103(6). 1195–1200. 169 indexed citations

15.

Berenson, James R., Sundar Jagannath, Bart Barlogie, et al.. (2005). Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 104(10). 2141–2148. 82 indexed citations

16.

Zangari, Maurizio, Kevin B. Najarian, Dixie Esseltine, et al.. (2005). The Anti-Myeloma Effect of Bortezomib Is Associated with Osteoblastic Activity.. Blood. 106(11). 510–510. 2 indexed citations

17.

Cristofanilli, Massimo, Ana M. González-Angulo, Daniel J. Booser, et al.. (2004). A phase II trial of PS-341 in metastatic breast cancer (MBC). Journal of Clinical Oncology. 22(14_suppl). 3102–3102. 1 indexed citations

18.

Fraser, Christophe, et al.. (2003). 193Normal hematopoietic stem cell function in mice following treatment with bortezomib. Biology of Blood and Marrow Transplantation. 9(2). 121–121. 14 indexed citations

19.

Grossbard, Michael L., Panos Fidias, John E. OʼToole, et al.. (1998). Anti‐B4‐blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma. British Journal of Haematology. 102(2). 509–515. 36 indexed citations

20.

Lynch, Thomas J., JM Lambert, F Coral, et al.. (1997). Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.. Journal of Clinical Oncology. 15(2). 723–734. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact